Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 2 patents
67 readers on Mendeley
  • Article usage
  • Citations to this article (283)

Advertisement

Free access | 10.1172/JCI110377

Role of Adherence in Cytopathogenic Mechanisms of Entamoeba Histolytica: STUDY WITH MAMMALIAN TISSUE CULTURE CELLS AND HUMAN ERYTHROCYTES

Jonathan I. Ravdin and Richard L. Guerrant

Division of Geographic Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908

Division of Infectious Diseases, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908

Find articles by Ravdin, J. in: JCI | PubMed | Google Scholar

Division of Geographic Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908

Division of Infectious Diseases, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908

Find articles by Guerrant, R. in: JCI | PubMed | Google Scholar

Published November 1, 1981 - More info

Published in Volume 68, Issue 5 on November 1, 1981
J Clin Invest. 1981;68(5):1305–1313. https://doi.org/10.1172/JCI110377.
© 1981 The American Society for Clinical Investigation
Published November 1, 1981 - Version history
View PDF
Abstract

The enteric pathogen, Entamoeba histolytica, appears to cause disease by adhering to and then destroying mucosal barriers. Using an in vitro method of studying the interaction of E. histolytica with target cells (Chinese hamster ovary [CHO] and human erythrocytes [RBC]), we examined the mechanism of amebic adherence and its role in lysis of target cells. Killing and phagocytosis of target cells by amebas ceases at 4°C, allowing observation of adherence. Amebas adhere to CHO cells at 4°C, 78.9% formed rosettes (amebas with ≥3 adherent CHO cells each) at 2 h. At 37°C, cytochalasins B and D inhibit adherence of amebas to CHO cells (P < 0.0005). Amebas adhere to and kill CHO cells in media with <0.1 μM calcium and magnesium plus 10 mM EDTA, indicating that divalent cations are not required in the medium. Adherence of amebas to human RBC was not ABO blood group specific and showed greater adherence to human than bovine or sheep RBC (P < 0.005). Neither Fc nor complement receptors were found on amebas by standard rosette studies. The amebic adherence receptor is not trypsin (0.125%) sensitive nor inhibited by trypan blue (1 mM). N-acetyl-d-galactosamine (GALNAc) inhibited the adherence of amebas to CHO cells and human RBC (0.1 g/100 ml or 4.5 mM GALNAc, P < 0.005) by binding to a receptor on the amebic surface. GALNAc abolishes amebic cytolysis of target CHO cells (determined by 111Indium oxine release from CHO cells, P < 0.001) but not amebic phagocytosis of CHO cells. By suspending ameba-CHO cells rosettes in dextran, we found that GALNAc (1%) reversibly inhibits amebic adherence (P < 0.0005) and that cytochalasins decrease amebic killing of adherent CHO cells (P < 0.025).

These findings indicate that the adherence of E. histolytica to target cells requires microfilament function, is via a specific amebic receptor that has affinity for GALNAc, and is required to lyse cells. Inhibition of the adherence of E. histolytica may alter the pathogenicity of this organism.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1305
page 1305
icon of scanned page 1306
page 1306
icon of scanned page 1307
page 1307
icon of scanned page 1308
page 1308
icon of scanned page 1309
page 1309
icon of scanned page 1310
page 1310
icon of scanned page 1311
page 1311
icon of scanned page 1312
page 1312
icon of scanned page 1313
page 1313
Version history
  • Version 1 (November 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (283)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
67 readers on Mendeley
See more details